Medium-Intensity Statins: Definition and Dosing
Medium-intensity (moderate-intensity) statins are defined as statin regimens that lower LDL-C by 30% to 49%, and include atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, lovastatin 40 mg, fluvastatin 40-80 mg, and pitavastatin 1-4 mg 1, 2.
Classification by Expected LDL-C Reduction
The 2018 ACC/AHA guideline stratifies statin therapy into three intensity categories based on the magnitude of LDL-C lowering 1, 2:
- High-intensity: ≥50% LDL-C reduction
- Moderate-intensity: 30-49% LDL-C reduction
- Low-intensity: <30% LDL-C reduction
Specific Moderate-Intensity Statin Regimens
The following statins and doses are classified as moderate-intensity 2:
Primary moderate-intensity options (evaluated in randomized controlled trials):
- Atorvastatin 10 mg or 20 mg
- Rosuvastatin 5 mg or 10 mg
- Simvastatin 20-40 mg (note: simvastatin 80 mg is NOT recommended by FDA due to myopathy risk)
- Pravastatin 40 mg or 80 mg
Additional moderate-intensity options:
- Lovastatin 40 mg
- Fluvastatin 40-80 mg (including extended-release formulations)
- Pitavastatin 1-4 mg
Important Clinical Considerations
Individual response variability: The LDL-C reduction percentages are population estimates from large trials. Individual patients may respond differently in clinical practice 2.
Asian populations: Certain Asian populations may demonstrate greater response to specific statins, potentially achieving higher LDL-C reductions at lower doses 1. Korean data suggests that some moderate-intensity regimens (atorvastatin 20 mg, rosuvastatin 10 mg) may achieve >50% LDL-C reduction in patients with baseline LDL-C ≥190 mg/dL 3.
Combination therapy alternative: Recent evidence indicates that moderate-intensity statin plus ezetimibe 10 mg achieves superior LDL-C target attainment (89.86% vs 70.77%) compared to high-intensity statin monotherapy in acute ischemic cerebrovascular disease, with comparable safety 4. This represents a viable alternative when high-intensity statins are not tolerated or contraindicated.
Dosing distinction within moderate-intensity: Within the moderate-intensity category, there is a functional difference between "lower-moderate" (atorvastatin 10 mg equivalent) and "higher-moderate" (atorvastatin 20 mg equivalent) regimens, with higher-moderate intensity showing better outcomes after CABG, particularly in acute coronary syndrome patients 5.